Boundless Bio, Inc.(BOLD) - 2024 Q4 - Annual Results

Financial Performance - Boundless Bio reported a cash position of $152.1 million as of December 31, 2024, an increase from$120.8 million in 2023[9] - The net loss for Q4 2024 was $16.4 million, compared to a net loss of$12.1 million in Q4 2023, and the full year net loss for 2024 totaled $65.4 million, up from$49.4 million in 2023[9] - The total operating expenses for the full year 2024 were $73.3 million, compared to$54.8 million in 2023[13] Research and Development - Research and Development (R&D) expenses for Q4 2024 were $13.3 million, up from$10.4 million in Q4 2023, and total R&D expenses for the full year 2024 were $55.3 million compared to$42.6 million in 2023[9] - Boundless Bio is advancing the BBI-355 Phase 1/2 POTENTIATE trial, with preliminary proof-of-concept data expected in the second half of 2025[1][2] - The company expects to report preliminary clinical proof-of-concept safety and antitumor activity data for BBI-355 in the second half of 2025[3] - Boundless Bio's ecDNA-directed therapeutic candidate, BBI-355, is being evaluated in a clinical trial targeting oncogene amplified cancers, which affect 14 to 17% of cancer patients[6] General and Administrative Expenses - General and Administrative (G&A) expenses for Q4 2024 were $5.0 million, compared to$3.4 million in Q4 2023, with total G&A expenses for the full year 2024 at $18.0 million versus$12.2 million in 2023[9] Leadership Changes - Boundless Bio appointed Robert Doebele, M.D., Ph.D., as Chief Medical Officer in February 2025, enhancing its leadership in oncology[4] Future Development Plans - The company is on track to nominate a development candidate for its novel Kinesin program by mid-2025, with an IND submission anticipated in the first half of 2026[1][2]